These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 35371002)

  • 41. Updating targets for natural killer/T-cell lymphoma immunotherapy.
    Xue W; Zhang M
    Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical features and treatment outcome of extranodal nasal-type NK/T-cell lymphoma of the extra-upper aerodigestive tract].
    Zhao YT; Wang Y; Qi SN; Yang Y; He X; Zhang YJ; Huang HQ; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Song YQ; Zhu J; Li YX
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):787-794. PubMed ID: 34289574
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunophenotypic characteristics and clinical relevance of CD56+ and CD56- extranodal nasal-type natural killer/T-cell lymphoma.
    Li YX; Wang H; Feng XL; Liu QF; Wang WH; Lv N; Jin J; Wang SL; Liu YP; Fang H; Song YW; Liu XF; Zhou LQ; Wang ZY; Yu ZH
    Leuk Lymphoma; 2011 Mar; 52(3):417-24. PubMed ID: 21323521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
    Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities.
    Kim WY; Nam SJ; Kim S; Kim TM; Heo DS; Kim CW; Jeon YK
    Leuk Lymphoma; 2015 Jun; 56(6):1778-86. PubMed ID: 25288491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma.
    Liu X; Cao D; Liu H; Ke X; Liu X; Xu X
    Clin Transl Oncol; 2024 Jan; 26(1):214-224. PubMed ID: 37351807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma.
    Liu JX; Liu X; Yang Y; Liu WP; Wang Y; He X; Zhang LL; Qu BL; Qian LT; Hou XR; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Zhang HL; Su H; Zhang YJ; Zhu J; Qi SN; Li YX; Song YQ
    Cancer Rep (Hoboken); 2023 May; 6(5):e1800. PubMed ID: 36919649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A controlling nutritional status score is an independent predictor for patients with newly diagnosed nasal-type extranodal NK/T-cell lymphoma based on asparaginase-containing regimens.
    Wu W; Ren K; Chen X; Li N; Zhou H; Jiang M; Yu Y; Zou L
    Cancer Med; 2023 Apr; 12(8):9439-9448. PubMed ID: 36866811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population.
    Chou CC; Tsao CF; Liao CK; You HL; Wang MC; Huang WT
    Exp Mol Pathol; 2021 Feb; 118():104577. PubMed ID: 33242451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma.
    Yang Y; Cao JZ; Lan SM; Wu JX; Wu T; Zhu SY; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Xu LM; Yuan ZY; Qi SN; Li YX
    JAMA Oncol; 2017 Jan; 3(1):83-91. PubMed ID: 27893001
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma.
    Chai Y; Qi F; Chen B; Gui L; Yang J; Qi S; Song Y; Li Y; Wei Y; Dong M
    Ann Hematol; 2020 Jun; 99(6):1303-1309. PubMed ID: 32333152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.
    Wei YC; Qi F; Zheng BM; Zhang CG; Xie Y; Chen B; Liu WX; Liu WP; Fang H; Qi SN; Zhang D; Chai Y; Li YX; Wang WH; Song YQ; Zhu J; Dong M
    Int J Cancer; 2023 Nov; 153(9):1643-1657. PubMed ID: 37539660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single-Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T-Cell Lymphoma.
    Li YQ; Luo CL; Jiang JX; He S; Liu Y; Yan WX; Xia Y; Cui Q; Huang Y; Lim JQ; Huang D; Hussein IN; Gao Y; Lin GW; Ling YH; Ma D; Zhang YT; Chan JY; Wei PP; Wang XX; Cheng CL; Xiong J; Zhao WL; Ong CK; Lim ST; Huang HQ; Peng RJ; Bei JX
    Adv Sci (Weinh); 2023 Dec; 10(36):e2303913. PubMed ID: 37949673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
    Kim M; Kim TM; Kim KH; Keam B; Lee SH; Kim DW; Lee JS; Jeon YK; Kim CW; Heo DS
    Ann Hematol; 2015 Mar; 94(3):437-44. PubMed ID: 25300500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group.
    Liu W; Yang Y; Qi S; Wang Y; He X; Zhang L; Qu B; Qian L; Hou X; Qiao X; Wang H; Li G; Zhang Y; Zhu Y; Cao J; Wu J; Wu T; Zhu S; Shi M; Xu L; Su H; Lin N; Zhu J; Li Y; Song Y
    Front Oncol; 2020; 10():583050. PubMed ID: 33718104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
    Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase 2 Clinical Trial of Simultaneous Boost Intensity Modulated Radiation Therapy With 3 Dose Gradients in Patients With Stage I-II Nasal Type Natural Killer/T-Cell Lymphoma: Long-Term Outcomes of Survival and Quality of Life.
    Niu S; Li Y; Shao H; Hu J; Wang J; Wang H; Zhang Y
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):770-780. PubMed ID: 37939733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Expression of CD7 and its correlation with prognosis in patients with NK/T-cell lymphoma].
    Fu XR; Wan WJ; Sun ZC; Zhang XD; Nan FF; Ge JR; Xia YQ; Zhang MZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):921-926. PubMed ID: 33333695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.